The U.S. National Institutes of Health (NIH) has given a Small Business Innovation Research (SBIR) grant totaling $2.4 million to Cutaneous NeuroDiagnostics (CND) to advance development of its Syn-One Test for diagnosing Parkinson’s and other neurodegenerative diseases. The SBIR grant (R44NS117214), which…

A new compound called CLR01, which works like a “molecular tweezer” to clear toxic protein clumps that accumulate in brain cells, could become a promising therapy to slow Parkinson’s disease progression, a study suggests. The study, “CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s…

Seelos Therapeutics has signed an agreement with Duke University in North Carolina to conduct a pre-clinical study of SLS-004, one of its gene therapy candidates, as a treatment for Parkinson’s disease. The proof-of-concept study will seek to determine if the investigational therapy can prevent or delay Parkinson’s disease…

Scientists have discovered new aggregates of alpha synuclein of various shapes that may play a key role in the onset of Parkinson’s disease. These new aggregates, which are larger than those described in previous studies, form in the presence of phospholipids — large fatty molecules that are…

The natural compound kaempferol — which acts as a potent antioxidant — can reduce the physical and behavioral symptoms of Parkinson’s in a fruit fly model of the disease. According to the researchers, this molecule may exert its protective effects by…

The small molecule anle138b has shown “excellent” safety and tolerability profiles in a first study in healthy volunteers, and reached therapeutic dose levels in the blood, according to its developer Modag. These results enabled Modag to secure an additional $1.4 million in funding from the Michael J.

The Michael J. Fox Foundation (MJFF) has awarded a total of $8.5 million to research teams at AC Immune, Mass General Brigham, and Merck to develop a way to detect the protein alpha-synuclein in the brains of people living with Parkinson’s disease. The three…

AC Immune anticipates advancing ACI-12589, its novel alpha-synuclein positron emission tomography (PET) tracer for Parkinson’s disease diagnosis, to clinical development in the last quarter of this year. Based on positive new data, the company made the announcement during an oral presentation at the virtual Alzheimer’s Association International…

Axial Biotherapeutics announced a $440,000 grant from the Michael J. Fox Foundation for Parkinson’s Research to support its efforts to develop a model that can mimic the nervous system of the gastrointestinal tract, and help in evaluating potential Parkinson’s disease treatments. Though Parkinson’s is primarily considered a neurodegenerative disorder,…

The U.S. Food and Drug Administration (FDA) will review Acadia Pharmaceutical’s application asking that Nuplazid (pimavanserin) also be approved to treat hallucinations and delusions associated with various forms of dementia-related psychosis, the company announced. The supplemental new drug application (sNDA) was granted standard review status, and the…